Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Operating Expenses (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Operating Expenses for 15 consecutive years, with $197.6 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses rose 26.18% to $197.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $716.6 million through Dec 2025, up 33.18% year-over-year, with the annual reading at $716.6 million for FY2025, 33.18% up from the prior year.
  • Operating Expenses hit $197.6 million in Q4 2025 for Corcept Therapeutics, roughly flat from $197.4 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $197.6 million in Q4 2025 to a low of $59.6 million in Q2 2021.
  • Historically, Operating Expenses has averaged $108.0 million across 5 years, with a median of $91.6 million in 2023.
  • Biggest five-year swings in Operating Expenses: fell 2.77% in 2021 and later skyrocketed 50.99% in 2024.
  • Year by year, Operating Expenses stood at $62.2 million in 2021, then grew by 29.6% to $80.6 million in 2022, then increased by 28.77% to $103.7 million in 2023, then surged by 50.99% to $156.6 million in 2024, then rose by 26.18% to $197.6 million in 2025.
  • Business Quant data shows Operating Expenses for CORT at $197.6 million in Q4 2025, $197.4 million in Q3 2025, and $167.8 million in Q2 2025.